Corporate ProfilescPharmaceuticals is a clinical-stage pharmaceutical company focused on developing and commercializing products that, through our proprietary platform, are designed to enable the subcutaneous administration of therapies previously limited to intravenous (IV) delivery — with the goal of transforming infused therapies, advancing patient care and reducing healthcare costs.
Stock Quote SCPH (Common Stock) $5.530.00 (0.00%)
ExchangeNASDAQ
Volume74,082
Today's Open$5.56
Previous Close$5.53
Data as of 06/20/18 4:00 p.m. ET

Data provided by Nasdaq. Minimum 15 minutes delayed.

Stock Chart
Stock chart for: SCPH.O.  Currently trading at $5.53 with a 52 week high of $18.17 and a 52 week low of $5.25.
Current News

Jun 13, 2018

scPharmaceuticals Receives Complete Response Letter from the FDA for FUROSCIX®

BURLINGTON, Mass., June 13, 2018 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq:SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs, today announced the Company received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the 505(b)(2) application for FUROSCIX®, a treatment candidate for edema, or flui

Read More >

May 31, 2018

scPharmaceuticals Inc. Provides Regulatory Update on FUROSCIX®

BURLINGTON, Mass., May 31, 2018 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq:SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs, today announced that, on May 30, 2018, the Company received a letter from the U.S. Food and Drug Administration (FDA) as part of the FDA’s ongoing review of the Company’s New Drug Application (NDA) for FUROSCIX®

Read More >

May 30, 2018

scPharmaceuticals Inc. to Present at the Jefferies 2018 Global Healthcare Conference

BURLINGTON, Mass., May 30, 2018 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq:SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs, today announced that John Tucker, president and chief executive officer and Troy Ignelzi, chief financial officer, will present at the Jefferies 2018 Global Healthcare Conference at 2:00 p.m. ET on Wednesday, Ju

Read More >

Upcoming Events
There are currently no events scheduled.